Publications
150
Citations
1,646
Est. group size
~21
Recurring co-author estimate
Active years
19
Publishing since 2008
Srinivas Devarakonda's work focuses on multiple myeloma, a cancer of plasma cells (a type of white blood cell), and related blood cancers. Recent work spans clinical guidelines, CAR T-cell and bispecific antibody therapies, infection risks after cell therapy, bone-related complications, and disparities in cancer survival outcomes. Much of this research draws on large real-world registries and clinical trial data to inform treatment and monitoring practices.
Publication output rose sharply around 2020-2021, peaked near 23 papers in 2020, and has since settled into a steadier pace of roughly 9-12 publications per year through 2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2026
- To treat or not to treat: a state-of-the-art overview of smoldering multiple myeloma
Frontiers in Hematology · 2026
- Impact of Infusion Timing on Safety and Efficacy of Anti-CD19 and Anti-BCMA CAR T Therapies
Transplantation and Cellular Therapy · 2026
- Infections in Patients with Relapsed Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel Therapy: A Real-World Analysis from CIBMTR
Transplantation and Cellular Therapy · 2026
- Diagnosis and Management of Multiple Myeloma With Central Nervous System Involvement
Journal of the National Comprehensive Cancer Network · 2026
- Editorial: Advances and new horizons in cellular therapies for leukemia and myeloma
Frontiers in Hematology · 2026
- Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
Transplantation and Cellular Therapy · 2026
- Effect of racial disparities on cancer survival in hematologic malignancies: a population-based analysis of SEER data (2009–2019)
Preventive Oncology & Epidemiology · 2025
- Time to initiation of antiresorptive agents in multiple myeloma to reduce skeletal related events
Frontiers in Hematology · 2025
- Myelodysplastic syndrome in Tanzania; The current status of management
Blood · 2025
- Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR
Blood · 2025
- Dual attack on multiple myeloma: targeting BCMA and CD19
AME Clinical Trials Review · 2025
- Demystifying the Delivery and Adverse Event Management of Bispecific Antibodies in the Community Setting
Blood · 2024
- Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
PubMed · 2023
- Evaluating depth of disparities in relation to relative survival rates: Analysis of SEER data.
Journal of Clinical Oncology · 2023
- Blood×33
- Biology of Blood and Marrow Transplantation×15
- Transplantation and Cellular Therapy×12
- Journal of Clinical Oncology×8
- Journal of the National Comprehensive Cancer Network×6
- Nidhi Sharma
Medicine · The Ohio State University
- Sherif S. Farag
Medicine · Indiana University
- Don Benson
Medicine · The Ohio State University
- Yi Zhao
Medicine · Indiana University
- Yvonne A. Efebera
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile